Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.380
-0.030 (-2.13%)
At close: Oct 31, 2024, 4:00 PM
1.390
+0.010 (0.72%)
After-hours: Oct 31, 2024, 6:39 PM EDT
Atossa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 13.15 | 14.04 | 12.61 | 11.31 | 8 | 10.62 | |
Research & Development | 17.42 | 17.33 | 15.08 | 9.21 | 6.61 | 6.65 | |
Operating Expenses | 30.57 | 31.38 | 27.69 | 20.52 | 14.61 | 17.27 | |
Operating Income | -30.57 | -31.38 | -27.69 | -20.52 | -14.61 | -17.27 | |
Interest & Investment Income | 4.72 | 4.34 | 0.88 | 0.01 | - | - | |
Other Non Operating Income (Expenses) | -0.06 | -0.07 | -0.15 | -0.09 | -3.22 | 0.03 | |
EBT Excluding Unusual Items | -25.91 | -27.1 | -26.96 | -20.61 | -17.83 | -17.24 | |
Gain (Loss) on Sale of Investments | - | -2.99 | - | - | - | - | |
Pretax Income | -25.91 | -30.09 | -26.96 | -20.61 | -17.83 | -17.24 | |
Earnings From Continuing Operations | -25.91 | -30.09 | -26.96 | -20.61 | -17.83 | -17.24 | |
Net Income | -25.91 | -30.09 | -26.96 | -20.61 | -17.83 | -17.24 | |
Preferred Dividends & Other Adjustments | - | - | - | - | 4.5 | - | |
Net Income to Common | -25.91 | -30.09 | -26.96 | -20.61 | -22.33 | -17.24 | |
Shares Outstanding (Basic) | 126 | 126 | 127 | 117 | 11 | 8 | |
Shares Outstanding (Diluted) | 126 | 126 | 127 | 117 | 11 | 8 | |
Shares Change (YoY) | -0.86% | -0.43% | 8.27% | 934.13% | 33.09% | 104.36% | |
EPS (Basic) | -0.21 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | |
EPS (Diluted) | -0.21 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | |
Free Cash Flow | -18.69 | -20.96 | -20.79 | -16.48 | -11.58 | -9.14 | |
Free Cash Flow Per Share | -0.15 | -0.17 | -0.16 | -0.14 | -1.02 | -1.08 | |
EBITDA | -30.55 | -31.35 | -27.68 | -20.5 | -14.56 | -17.21 | |
D&A For EBITDA | 0.03 | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | |
EBIT | -30.57 | -31.38 | -27.69 | -20.52 | -14.61 | -17.27 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.